Springworks Therapeutics Intrinsic Value Calculator – SpringWorks Therapeutics’ Stock Jumps 18% After FDA Approval of Ogsiveo
November 29, 2023
☀️Trending News
SPRINGWORKS ($NASDAQ:SWTX): SpringWorks Therapeutics, a biopharmaceutical company focused on developing therapies for rare diseases, had reason to celebrate this week after the FDA approved its lead drug Ogsiveo for the treatment of multiple myeloma. The news caused its stock to jump 18% in after-hours trading, a sign of optimism from investors for the potential of the drug. Ogsiveo is the first drug from the company to be approved for use by the FDA. It is a targeted therapy that works by inhibiting a protein that fuels cancer growth, thus slowing down the disease’s progression. The approval of Ogsiveo is a major milestone for SpringWorks and the company’s future prospects.
SpringWorks plans to continue research and development in new treatments for rare diseases as well as providing support programs so that patients can access their drugs more easily. Investors have taken note of this, as evidenced by the stock’s jump in value. SpringWorks Therapeutics is well-positioned to become a major player in the fight against rare diseases.
Analysis – Springworks Therapeutics Intrinsic Value Calculator
GoodWhale has conducted an analysis of SPRINGWORKS THERAPEUTICS‘s fundamentals and has determined that the intrinsic value of their stock is around $33.7, which is calculated by our proprietary Valuation Line. This means that the stock is currently being traded at $20.8 – which is a 38.3% undervaluation of its true worth. As such, we recommend taking advantage of this opportunity and investing in SPRINGWORKS THERAPEUTICS stock. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Springworks Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -304.96 | -130.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Springworks Therapeutics. More…
| Operations | Investing | Financing |
| -214.29 | -161.05 | -2.13 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Springworks Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 467.65 | 72.75 | 6.31 |
Key Ratios Snapshot
Some of the financial key ratios for Springworks Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -132.4% |
| FCF Margin | ROE | ROA |
| -93.8% | -47.7% | -43.2% |
Peers
The company is focused on developing and commercializing therapies for the treatment of rare and underserved diseases. SpringWorks Therapeutics Inc’s competitors include Aadi Bioscience Inc, Avalo Therapeutics Inc, and Immunic Inc.
– Aadi Bioscience Inc ($NASDAQ:AADI)
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company’s lead product candidate is AB-101, a small molecule inhibitor of the PI3K/mTOR pathway, which is in Phase I clinical trials for the treatment of solid tumors. Aadi Bioscience Inc has a market cap of 317.87M as of 2022, a Return on Equity of -28.05%.
– Avalo Therapeutics Inc ($NASDAQ:AVTX)
Avalo Therapeutics Inc is a clinical stage biopharmaceutical company developing novel cancer therapies. The company’s market cap as of 2022 is 50.93M and its ROE is 729.23%. Avalo’s pipeline of products includes two clinical stage programs: AVL-292, a first-in-class, small molecule inhibitor of checkpoint kinase 1 (Chk1) for the treatment of solid tumors, and AVL-181, a first-in-class, small molecule inhibitor of checkpoint kinase 2 (Chk2) for the treatment of hematologic malignancies.
– Immunic Inc ($NASDAQ:IMUX)
Immunic, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing oral therapies for the treatment of immune-mediated diseases. Its pipeline includes IMU-838 that is in Phase II clinical trial for the treatment of plaque psoriasis and atopic dermatitis; and IMU-935, which is in Phase I clinical trial for the treatment of autoimmune diseases. The company was founded by Daniel M. Adelman, Michael J. Brenner and William T. Symonds on December 15, 2006 and is headquartered in New York, NY.
Summary
SpringWorks Therapeutics saw its stock price rally 18% after the FDA granted approval for its drug, Ogivio. The approval was a major victory for the company and is expected to have a positive effect on its share price.
However, the stock price moved down the same day, likely due to profit taking. Investors should watch SpringWorks closely going forward as their success in the future will be determined by how well they can capitalize on the Ogivio approval. Analysts are optimistic that the company can achieve long-term success, though caution is warranted as the stock market is unpredictable and could move in either direction. Investors should consider adding SpringWorks to their portfolio as it offers potential for strong returns.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
